Non-Small-Cell Lung Cancer | Unmet Need | US/EU | 2019

EGFR-mutation-status determination is a mandatory step in the treatment algorithm for patients with advanced non-small-cell lung cancer (NSCLC), highlighting the importance of biomarker-driven targeted therapies in this indication. EGFR tyrosine kinase inhibitors (TKIs)—Tarceva (Roche/ Genentech), Iressa (AstraZeneca), Tagrisso (AstraZeneca), and Gilotrif/Giotrif (Boehringer Ingelheim)—have been the conventional first-line choice of therapy in EGFR-mutation-positive metastatic nonsquamous NSCLC for many years. In 2018, the next-generation EGFR TKI Vizimpro (Pfizer) was approved in the United States for the first-line treatment of patients with EGFR mutations. The PD-1 inhibitor Opdivo (Bristol-Myers Squibb) for treatment of EGFR-mutation-positive metastatic nonsquamous NSCLC is another option for patients who have progressed on EGFR TKIs. However, resistance to EGFR TKIs and treatment-related adverse events remain key unmet needs in the metastatic setting, generating opportunity for novel therapies to gain an upper hand over the existing drugs in the NSCLC treatment landscape.


  • What are the treatment drivers and goals for EGFR-mutation-positive metastatic nonsquamous NSCLC?
  • How do current therapies, such as Opdivo, perform on key treatment drivers and goals for EGFR-mutation-positive metastatic nonsquamous NSCLC?
  • What are the prevailing areas of unmet need and opportunity in EGFR-mutation-positive metastatic nonsquamous NSCLC?
  • What trade-offs across different clinical attributes and price are acceptable to surveyed oncologists for hypothetical new treatment options in first-line EGFR-mutation-positive metastatic nonsquamous NSCLC?


Unmet Need provides quantitative insight into U.S. and European physician perceptions of key treatment drivers and goals and the current level of unmet need for a specific disease. Commercial opportunities are analyzed, and the extent to which emerging therapies may capitalize on these opportunities is evaluated.

Markets covered: United States, United Kingdom, France, Germany.

Primary research: Survey of 61 medical oncologists in US and 30 medical oncologists in Europe fielded in March 2019.

Key companies: Astellas, AstraZeneca, Boehringer Ingelheim, Bristol-Myers Squibb, Genentech, Pfizer, Teva.

Key drugs: Tarceva, Iressa, Gilotrif/Giotrif, Tagrisso, Vizimpro, Avastin (in combination with paclitaxel and carboplatin), Opdivo.

Login to access report

launch Related Market Assessment Reports